Single Chain FVIII Polypeptide Expression for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A, characterized by factor VIII deficiency, require frequent intravenous injections due to the short half-life of plasma-derived and recombinant FVIII products, leading to painful and inconvenient administration, and lack prolonged hemostatic protection.
Innovation Solution
Development of a recombinant cell line producing a single chain FVIII polypeptide with a half-life extending moiety, such as an immunoglobulin constant region or albumin binding polypeptide, to create a long-acting Factor VIII with improved stability and reduced administration frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If plasma-derived and recombinant FVIII products are used for treatment, then hemostatic protection is provided, but the short half-life requires frequent intravenous injections
Solution Approach 1:
The patent modifies the molecular structure of Factor VIII by fusing it to albumin-binding moieties, changing the physical-chemical parameters of the protein to increase its serum half-life from 8-12 hours to potentially several days, thereby reducing administration frequency
Solution Approach 2:
The invention creates a composite protein structure combining Factor VIII with albumin-binding domains or PEG chains, forming a hybrid molecule that leverages the long circulation half-life of albumin/PEG while maintaining FVIII's hemostatic function
2Reliability
If frequent intravenous injections are administered, then adequate FVIII activity levels are maintained, but patient quality of life deteriorates due to pain and inconvenience
Solution Approach 1:
By engineering FVIII variants with altered pharmacokinetic parameters (extended half-life), the treatment regimen can be changed from frequent daily/weekly injections to less frequent monthly or even quarterly administrations, improving patient convenience while maintaining reliable FVIII activity
3Productivity
If B domain deletion is performed to simplify FVIII structure, then expression efficiency improves, but the molecular complexity reduction is limited
Solution Approach 1:
The patent divides the FVIII molecule into functional domains and selectively removes the large B domain (approximately 500 amino acids), retaining only the essential A and C domains required for hemostatic activity, thereby simplifying the structure while maintaining function and improving expression
Solution Approach 2:
The B domain, which is non-essential for FVIII activity but complicates expression and purification, is extracted and removed from the FVIII sequence, creating a streamlined molecule that is easier to produce recombinantly
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.